Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient

Area of Science:

• Infectious Diseases
• Hematology
• Gastroenterology

Background:

• Clostridioides difficile (CD) is a major cause of diarrhea in hospitalized patients.
• Allogeneic hematopoietic cell transplant (allo-HCT) recipients face increased risk of CD infection (CDI) due to hospitalizations, immunosuppression, and antibiotics.
• CDI can severely impact allo-HCT patients, prolonging hospitalization, affecting the gut microbiome, and worsening outcomes.

Purpose of the Study:

• To review the diagnosis and management of Clostridioides difficile infection (CDI) in adult and pediatric patients undergoing allogeneic hematopoietic cell transplant (allo-HCT).
• To discuss current treatment guidelines and emerging therapies for CDI in this vulnerable population.

Main Methods:

• Review of current literature and clinical guidelines for CDI diagnosis and treatment in allo-HCT patients.
• Analysis of treatment recommendations for adult and pediatric populations, including first-line agents, alternatives, and recurrence prevention.

Main Results:

• In adults, fidaxomicin is recommended first-line, with vancomycin as an alternative. Bezlotoxumab can prevent recurrence.
• Pediatric treatment primarily uses vancomycin and metronidazole, though fidaxomicin is expected to become standard.
• Fecal microbiota transplantation is not routinely recommended for allo-HCT patients due to limited safety data.

Conclusions:

• CDI is a significant complication in allo-HCT patients requiring careful diagnosis and management.
• Treatment strategies differ between adult and pediatric populations, with evolving recommendations.
• Further research is needed on novel therapies like fecal microbiota transplantation in the allo-HCT context.